NEURONOVA
NeuroNova is develops drug targets and candidates that demonstrate potential in the treatment of neurodegenerative diseases. Its products include sNN0029, a drug candidate for the treatment of amyotrophic lateral sclerosis; and sNN0031, a drug candidate for the treatment of moderate to severe stage Parkinson’s disease that is designed to act on neural stem and progenitor cells in the brain.
NEURONOVA
Industry:
Biotechnology Medical Pharmaceutical
Founded:
1998-01-01
Address:
Stockholm, Stockholms Lan, Sweden
Country:
Sweden
Website Url:
http://www.neuronova.com
Status:
Active
Contact:
+46 87 86 09 00
Similar Organizations
More informations about "NeuroNova"
NeuroNova - Crunchbase Company Profile & Funding
NeuroNova is develops drug targets and candidates that demonstrate potential in the treatment of neurodegenerative diseases. Its products include sNN0029, a drug candidate for the treatment …See details»
NeuroNova Company Profile 2024: Valuation, Investors
Developer and provider of novel therapies for the treatment of disorders of the central nervous system. The company also develops novel therapeutic products based on neurogenesis in …See details»
NeuroNova - VentureRadar
Website: http://www.neuronova.com/ We believe therapeutic neurogenesis and neuroprotection can revolutionize the treatment of several currently incurable neurodegenerative diseases, …See details»
NeuroNova AB - Stockholm, Sweden - bionity.com
NeuroNova is develops drug targets and candidates that demonstrate potential in the treatment of neurodegenerative diseases. Its products include sNN0029, a drug candidate for the treatment …See details»
Neuronova AG - VentureRadar
Find out more about Neuronova AG including the VentureRadar Innovation and Growth scores, Similar Companies and more.See details»
NeuroNova (Other Commercial Products) - PitchBook
Jan 1, 2024 · Developer of artificial intelligence chips designed to deliver high performance with lower energy consumption. The company offers advanced chip technology, enabling …See details»
Newron to acquire Swedish neurogenesis company NeuroNova AB
Jun 13, 2012 · NeuroNova, founded by scientists from Karolinska Institutet, has extensive experience in the field of neurogenesis. The company's compounds act by generating new …See details»
Newron Pharmaceuticals acquires NeuroNova - 2012-06-13
Jun 13, 2012 · NeuroNova NeuroNova is develops drug targets and candidates that demonstrate potential in the treatment of neurodegenerative diseases. Acquiring Organization: Newron …See details»
NeuroNova - Products, Competitors, Financials, Employees, …
CLD-101 is the lead therapeutic candidate in Calidi’s NeuroNova program, comprising tumor-tropic neural stem cells (NSCs) that deliver an oncolytic adenovirus (NSC-CRAd-S-pk7) …See details»
NeuroNova - Crunchbase
Developing innovative small molecule drugs to treat eye diseases with high unmet medical need. NeuroNova is develops drug targets and candidates that demonstrate potential in the …See details»
Karolinska spin out NeuroNova agrees license with Genentech
Mar 18, 2009 · NeuronNova has agreed a license with Genentech that gives NeuroNova the right to use VEGF (Vascular Endothelial Growth Factor) in the treatment of amyotrophic lateral …See details»
NeuroNova Centre for Mindful Solutions Inc. | LinkedIn
NeuroNova Centre for Mindful Solutions Inc. Mental Health Care Port Hope, Ontario 168 followers Offering Trauma Sensitive/Informed Mindfulness-Based Chronic Pain Management training for...See details»
Home [https:]
NeuroNova Media is a pioneering organization dedicated to empowering children and youth with neurodiverse challenges through engaging digital and print media. Our mission is to create a …See details»
Neuronova - 360cap.vc
Neuronova develops an ultra-low-power processor, a groundbreaking technology that reduces energy consumption by 1000x, allowing AI to run on battery-powered smart devices and …See details»
Newron snaps up Karolinska CNS spinoff in $20M buyout deal
Jun 13, 2012 · The Italian biotech has executed a deal to buy Sweden's NeuroNova in an all-share deal that values the little Karolinska Institutet spinoff at a little less than $20 million.See details»
Calidi Biotherapeutics Announces Presentation of Clinical Study for ...
Dec 13, 2023 · Calidi’s collaborator: City of Hope Comprehensive Cancer Center dosed the first patient in June 2023 in a Phase 1 clinical trial of NeuroNova (NNV2) and has dosed 6 patients …See details»
Calidi Biotherapeutics Announces FDA Authorization of IND for a …
Once the phase 1 trial is funded, it will address the safety and tolerability of administering serial doses of NeuroNova in adult patients with recurrent histologically confirmed high-grade …See details»
Calidi Biotherapeutics Announces Presentation of Clinical Study for ...
Dec 13, 2023 · Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today …See details»
Oncolytic viruses: past and present - European Pharmaceutical …
Aug 25, 2022 · Now, clinical trials are assessing an allogeneic therapy for glioblastoma called NeuroNova, which maximises the power of an oncolytic virus by hiding it from the patient’s …See details»
NeuroNova Centre
NeuroNova Centre offers help with Chronic Pain Management in Port Hope, Ontario including anxiety, headaches, migraines, fibromyalgia, & more.See details»